Hi @jlgread,
Good question, the tantalum credits have been already been factored and netted off in the ASIC cost calculations which were provided in the recent H2 guidance figures that LTR published on 11 November 2024. Tony Ottaviano mentioned during the webcast Q&A section that these H2 guidance figures (which included the tantalum credits being netted off the AISC figures) could also be used as an indicator for what the last few month of December 24 quarter might also look like.
I have placed a copy of the slide below and underlined footnote #1 which refers to this.
If I were to include tantalum credits as a seperate revenue item, I would also need to increase the ASIC production costs too. For simplicity I decided it would be better to keep the tantalum credits netted off from the AISC for now until we had further information on these.
I am also interested as well to see what Tony mentions about these in the webcast and happy to make any adjustments as necessary to my workings. If the pricing for the Tantalum credits have been changing significantly, then there is a good reason to seperate out these amounts and begin to deviate away from the H2 guidance figures... For royalties, this is actually something I have already done in my spreadsheet as we saw a great shift in spodumene pricing and the AISC figures were based on a spodumene price of USD $790/tonne (footnote #3 of the slide).
I will have to await the webcast commentary, but great question though!
Cheers,
CK
- Forums
- ASX - By Stock
- LTR
- Ann: December 2024 Quarterly Webcast
LTR
liontown resources limited
Add to My Watchlist
2.86%
!
72.0¢

Ann: December 2024 Quarterly Webcast, page-47
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
72.0¢ |
Change
0.020(2.86%) |
Mkt cap ! $1.749B |
Open | High | Low | Value | Volume |
71.5¢ | 74.5¢ | 71.0¢ | $7.433M | 10.20M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 123123 | 72.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
72.5¢ | 30000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 80430 | 0.720 |
2 | 10760 | 0.715 |
6 | 124584 | 0.710 |
1 | 200000 | 0.705 |
3 | 11471 | 0.700 |
Price($) | Vol. | No. |
---|---|---|
0.725 | 30000 | 1 |
0.730 | 97500 | 6 |
0.735 | 354013 | 6 |
0.740 | 154624 | 10 |
0.745 | 217517 | 11 |
Last trade - 16.14pm 27/06/2025 (20 minute delay) ? |
Featured News
LTR (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online